Search results for "From ACP Internist Weekly"
Rosuvastatin, atorvastatin compared on effectiveness, safety in industry-funded trial
Analysis of a randomized trial in South Korea found that patients randomized to rosuvastatin developed type 2 diabetes requiring medication at a rate of 7.2%, compared to 5.3% among those given atorvastatin.
https://diabetes.acponline.org/archives/2023/11/10/8.htm
10 Nov 2023
Almost 4 in 10 with type 1 diabetes were diagnosed in adulthood
Peak diagnosis age was approximately 15 years, and the median age of diagnosis was 24 years, but 37% of adults with type 1 diabetes reported having been diagnosed after age 30 years in a recent study.
https://diabetes.acponline.org/archives/2023/10/13/9.htm
13 Oct 2023
‘Night owls' more likely to have unhealthy lifestyles, higher diabetes risk
In a retrospective cohort study, people with an evening chronotype were more likely to smoke, sleep poorly, and be physically inactive and had a 72% higher risk for diabetes than those with a morning chronotype.
https://diabetes.acponline.org/archives/2023/10/13/11.htm
13 Oct 2023
Higher aspirin dose no more effective for CV prevention in high-risk patients with diabetes
A subgroup analysis of a randomized trial found that patients with diabetes and atherosclerotic cardiovascular (CV) disease had similar outcomes whether they took 81 mg or 325 mg of aspirin daily.
https://diabetes.acponline.org/archives/2023/10/13/10.htm
13 Oct 2023
SGLT-2 inhibitors reduced gout flares in patients with diabetes, gout
New users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors had about half the risk of an ED visit or hospitalization for a gout flare as matched patients taking dipeptidyl peptidase-4 inhibitors, a cohort analysis found.
https://diabetes.acponline.org/archives/2023/08/11/7.htm
11 Aug 2023
Nonsugar sweeteners should not be used for weight loss, WHO guideline states
The World Health Organization (WHO) cited a lack of evidence suggesting that short-term use of nonsugar sweeteners affected body weight or other measures of adiposity, as well as possible long-term undesirable effects on noncommunicable diseases and death.
https://diabetes.acponline.org/archives/2023/06/09/7.htm
9 Jun 2023
Large review compares benefits, harms of drugs to treat type 2 diabetes
High-certainty evidence indicated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce all-cause death, while finerenone probably also reduced mortality based on moderate-certainty evidence.
https://diabetes.acponline.org/archives/2023/05/12/6.htm
12 May 2023
Nocturnal hypoglycemia underdiagnosed in older patients on insulin for type 2 diabetes
An industry-funded study of patients age 75 years and older who were taking insulin for type 2 diabetes found that almost two-thirds (65.2%) experienced nocturnal hypoglycemia during a 28-day study period.
https://diabetes.acponline.org/archives/2023/04/14/6.htm
14 Apr 2023
Overweight, obesity poorly managed in type 1 diabetes
While U.S. adults with type 1 diabetes have rates of overweight and obesity virtually identical to those in the general adult population, only about 50% received lifestyle recommendations for weight management from clinicians or tried lifestyle modifications.
https://diabetes.acponline.org/archives/2023/03/10/9.htm
10 Mar 2023
ADA updates diabetes standards of care for 2023
The American Diabetes Association (ADA) has changed its recommendations on hypertension cutoffs, use of statins, and treatment of patients with diabetes and chronic kidney disease, among other topics.
https://diabetes.acponline.org/archives/2023/01/13/5.htm
13 Jan 2023
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/12/09/7.htm
9 Dec 2022
GLP-1 receptor agonists associated with thyroid cancer
Patients taking a glucagon-like peptide-1 (GLP-1) receptor agonist had about one and a half times the risk of developing thyroid cancer compared to similar controls, according to an observational French study.
https://diabetes.acponline.org/archives/2022/12/09/6.htm
9 Dec 2022
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/11/11/6.htm
11 Nov 2022
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://diabetes.acponline.org/archives/2022/10/14/8.htm
14 Oct 2022
ADA, EASD update guidance on managing hyperglycemia
An updated consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) addressed social drivers of health, lifestyle modifications, and new drug classes for type 2 diabetes.
https://diabetes.acponline.org/archives/2022/10/14/7.htm
14 Oct 2022
Treatment pathways compared for diabetic peripheral neuropathy
Amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective for controlling pain, a recent study found.
https://diabetes.acponline.org/archives/2022/09/16/7.htm
16 Sep 2022
Targeting social needs may help improve type 2 diabetes outcomes, review finds
A systematic review found that HbA1c levels were improved significantly by food supplementation with referral and diabetes support, financial incentives with education and skills training, housing relocation with counseling support, and the integration of nonmedical interventions into medical care.
https://diabetes.acponline.org/archives/2022/07/08/6.htm
8 Jul 2022
No additional benefit seen for self-monitored blood glucose with community health worker support
In a small trial, patients with insulin-treated diabetes were randomly assigned to usual care, a lottery incentive for daily self-monitored blood glucose, or the lottery plus support from a community health worker if needed.
https://diabetes.acponline.org/archives/2022/06/10/6.htm
10 Jun 2022
Tailoring diabetes screening by race, ethnicity may lead to earlier diagnosis
Researchers used data from the National Health and Nutrition Examination Survey to determine the body mass index and age thresholds for diabetes screening in major racial/ethnic minority populations.
https://diabetes.acponline.org/archives/2022/05/13/8.htm
13 May 2022
Paternal metformin use associated with major birth defects
A prospective registry-based study in Denmark found that offspring of men who filled one or more prescriptions for metformin during the three months of developing fertilizing sperm were more likely to have a birth defect, while insulin and sulfonylureas were not associated with increased risk.
https://diabetes.acponline.org/archives/2022/04/08/6.htm
8 Apr 2022